A large Japanese cohort study finds that elevated serum IgG4 may identify peripheral nerve damage in eosinophilic ...
Big Pharma-backed Nuvig Therapeutics has halted one of two trials for its sole clinical asset after determining the program ...
For Rare Disease Day and Week, ICT presents: Rare autoimmune diseases affect millions worldwide, yet vaccine guidance for these patients remains complex. Understanding disease mechanisms, ...
Cases of a rare autoimmune disease surged between 2020 and 2022 in Yorkshire, England, peaking in 2021. COVID-19 infection and its vaccines possibly contributed to the rise, a recent study in The ...
A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare autoimmune disease of the peripheral nervous system. This treatment modifies ...
A Wisconsin family says they are working to get their beloved family member home after becoming hospitalized during a family ...
MOG antibody-associated disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients contains antibodies against myelin oligodendrocyte glycoprotein (MOG), a ...
Not a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the ...
After three patient deaths and the indefinite suspension of several clinical trials, questions exist about the potential future of CAR T-cell research for autoimmune diseases.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
Bryan Johnson is battling this rare autoimmune disease: Biohacker shares his health issue in recent post
For a while now, Bryan Johnson has been on a mission to outsmart aging, and the world has been taking notes. He’s the American entrepreneur and venture capitalist turned longevity enthusiast who ...
RBC Upgrades Lakefront Biotherapeutics to Outperform From Sector Perform, Adds Speculative Risk, Raises Price Target to $45 From $26 MT Sep. 15 Lakefront Biotherapeutics NV Presents at Morgan Stanley ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results